Chief Operating Officer Liane Rae Teplitsky of Pulse Biosciences Inc. purchased 2,025 shares of common stock in two separate open-market transactions, totaling $99,971.
On August 31, 2026, Teplitsky acquired 1,024 shares at a weighted average price of $48.80 per share, with individual transaction prices ranging from $48.76 to $48.80. The following day, September 1, 2026, she purchased an additional 1,001 shares at $49.95 per share. The company confirmed all transactions occurred within an open trading window and complied with applicable securities regulations.
Following the purchases, Teplitsky holds a total of 4,095 shares of Pulse Biosciences common stock, with a current market value of approximately $216,000 based on recent trading prices. Pulse Biosciences shares were last quoted at $52.68, near the 52-week high of $54.39 and up 284% year-to-date.
The insider activity follows mixed financial results for Pulse Biosciences in the second quarter of 2026. The company reported adjusted losses of $0.36 per share, exceeding Wall Street estimates of $0.28, and revenue of $400,000, below the anticipated $600,000. Analysts at Canaccord raised the price target to $43 from $32 while maintaining a buy rating, while Needham initiated coverage with a buy rating and a $58 price target, citing the company’s next-generation pulsed field ablation platform technology.
Pulse Biosciences also highlighted progress in its pivotal clinical trial for atrial fibrillation and ongoing advancements in its nanosecond pulsed field ablation system.
